Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Watsco Up Nearly 6%, on Pace for Largest Percent Increase Since April 2025 -- Data Talk

Watsco Up Nearly 6%, on Pace for Largest Percent Increase Since April 2025 -- Data Talk

Dow JonesDow Jones2026/10/22 18:52

Watsco, Inc. (WSO) is currently at $323.07, up $18.04 or 5.91%

--Would be highest close since Sept. 23, 2026, when it closed at $325.37

--On pace for largest percent increase since April 9, 2025, when it rose 7.77%

--Currently up three consecutive days; up 9.89% over this period

--Best three day stretch since the three days ending Feb. 18, 2025, when it rose 12.75%

--Up 6.73% month-to-date

--Down 4.12% year-to-date

--Down 43.2% from its all-time closing high of $568.78 on Nov. 25, 2024

--Down 10.03% from 52 weeks ago (Oct. 23, 2025), when it closed at $359.08

--Down 29.28% from its 52-week closing high of $456.86 on April 27, 2026

--Up 15.42% from its 52-week closing low of $279.90 on Oct. 9, 2026

--Traded as high as $323.87; highest intraday level since Sept. 24, 2026, when it hit $326.70

--Up 6.18% at today's intraday high; largest intraday percent increase since Nov. 21, 2025, when it rose as much as 6.33%

All data as of 2:51:03 PM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 22, 2026 14:52 ET (18:52 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear

Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

智通财经•2026/11/04 03:53

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs

AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.

智通财经•2026/11/04 02:51